← All Geovax Labs, INC filings

Geovax Labs, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
GOVX
Geovax Labs, INC
10-K: GeoVax Labs Reports 2025 Financials, Advances Vaccine Pipeline
GeoVax Labs, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing progress in its vaccine development programs for mpox, smallpox, COVID-19, and cancer, alongside financial performance and ongoing funding needs.
NASDAQ
GOVX
Geovax Labs, INC
10-K: GeoVax Labs Reports FY 2024 Results, Highlights COVID-19 Vaccine Progress and BARDA Funding
GeoVax Labs' 10-K filing details the company's financial results for 2024 and provides updates on its vaccine and immunotherapy programs, including significant BARDA funding for its COVID-19 vaccine candidate.
NASDAQ
GOVX
Geovax Labs, INC
10-K/A: GeoVax Labs Files Amended 10-K Report, Includes Updated Executive Certifications
GeoVax Labs has filed an amendment to its annual report on Form 10-K to include information required in Part III of the original filing and new certifications from its principal executive and financial officers.
NASDAQ
GOVX
Geovax Labs, INC
10-K: GeoVax Labs Inc. Files 10-K Annual Report, Outlines Progress in Vaccine and Immunotherapy Development
GeoVax Labs Inc. has released its 10-K annual report, detailing its financial results and progress in developing vaccines and immunotherapies for infectious diseases and cancers.